Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving AML care beyond one-size-fits-all induction and transplant algorithms.
A new review article outlines the latest research and results into programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors for the treatment of myelodysplastic syndromes (MDS) ...
Do I Know You? Patient Privacy and Consent in the Age of Social Media Since 2017, the number of agents for acute myeloid leukemia (AML) has rapidly expanded. Given ...
What Is Secondary Acute Myeloid Leukemia? Secondary acute myeloid leukemia (sAML) is a type of acute myeloid leukemia (AML), a kind of blood cancer that starts in white blood cells that grow in your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results